| Added by | tchardes |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME) |
| Creator | Dano et al. |
| Author | D. Dano |
| Author | A. Monneur |
| Author | N. Quenel-Tueux |
| Author | C. Levy |
| Author | M.-A. Mouret-Reynier |
| Author | B. Coudert |
| Author | A. Mailliez |
| Author | J.-M. Ferrero |
| Author | S. Guiu |
| Author | M. Campone |
| Author | T. de La Motte Rouge |
| Author | T. Petit |
| Author | B. Pistilli |
| Author | F. Dalenc |
| Author | G. Simon |
| Author | F. Lerebours |
| Author | S. Chabaud |
| Author | F. Bertucci |
| Abstract | BACKGROUND: Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low incidence, the prognosis of IBC at metastatic stage is poorly described. MATERIALS AND METHODS: This study aimed to compare OS calculated from the diagnosis of metastatic disease between IBC patients and non-IBC patients in the Epidemiological Strategy and Medical Economics database (N = 16?702 patients). Secondary objectives included progression-free survival (PFS) after first-line metastatic treatment, identification of prognostic factors for OS and PFS, and evolution of survival during the study period. RESULTS: From 2008 to 2014, 7465 patients with metastatic breast cancer and known clinical status of their primary tumor (T) were identified (582 IBC and 6883 non-IBC). Compared with metastatic non-IBC, metastatic IBC was associated with less hormone receptor-positive (44% versus 65.6%), more human epidermal growth factor receptor 2-positive (30% versus 18.6%), and more triple-negative (25.9% versus 15.8%) cases, more frequent de novo M1 stage (53.3% versus 27.7%; P < 0.001), and shorter median disease-free interval (2.02 years versus 4.9 years; P < 0.001). With a median follow-up of 50.2 months, median OS was 28.4 months [95% confidence interval (CI) 24.1-33.8 months] versus 37.2 months (95% CI 36.1-38.5 months) in metastatic IBC and non-IBC cases, respectively (P < 0.0001, log-rank test). By multivariate analysis, OS was significantly shorter in the metastatic IBC group compared with the metastatic non-IBC group [hazard ratio = 1.27 (95% CI 1.1-1.4); P = 0.0001]. Survival of metastatic IBC patients improved over the study period: median OS was 24 months (95% CI 20-31.9 months), 29 months (95% CI 21.7-39.9 months), and 36 months (95% CI 27.9-not estimable months) if diagnosis of metastatic disease was carried out until 2010, between 2011 and 2012, and from 2013, respectively (P = 0.003). CONCLUSION: IBC is independently associated with adverse outcome when compared with non-IBC in the metastatic setting. |
| Publication | ESMO open |
| Volume | 6 |
| Issue | 4 |
| Pages | 100220 |
| Date | 2021-08 |
| Journal Abbr | ESMO Open |
| Language | eng |
| DOI | 10.1016/j.esmoop.2021.100220 |
| ISSN | 2059-7029 |
| Short Title | Metastatic inflammatory breast cancer |
| Library Catalog | PubMed |
| Extra | PMID: 34303929 PMCID: PMC8327489 |
| Tags | clinic, inflammatory breast cancer, metastatic breast cancer, multimodal therapy, real-life study |
| Date Added | 2021/10/01 - 17:23:56 |
| Date Modified | 2021/10/01 - 17:28:08 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
